Trial · NCT07881601
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Flow-Mediated Dilation (FMD) | Baseline, Week 4, Week 8 | Change in Flow-Mediated Dilation (FMD), a measure of vascular endothelial function. |
| Secondary | Change in Total Plasma CoQ10 Concentration | Baseline, Week 4, Week 8 | Change from baseline in the absolute concentration of total coenzyme Q10 (CoQ10) in plasma, measured in μg/mL. |
| Secondary | Change in Plasma Ubiquinol Concentration | Baseline, Week 4, Week 8 | Change from baseline in the absolute concentration of reduced coenzyme Q10 (ubiquinol) in plasma, measured in μg/mL. |
| Secondary | Change in Plasma Ubiquinone Concentration | Baseline, Week 4, Week 8 | Change from baseline in the absolute concentration of oxidized coenzyme Q10 (ubiquinone) in plasma, measured in μg/mL. |
| Secondary | Change in Ratio of Reduced to Total CoQ10 | Baseline, Week 4, Week 8 | Change from baseline in the ratio of reduced CoQ10 (ubiquinol) to total CoQ10 in plasma. |
| Secondary | Change in Plasma Nitric Oxide (NO) | Baseline, Week 4, Week 8 | Change from baseline in plasma nitric oxide (NO), assessed by nitrite/nitrate quantification. |
| Secondary | Change in LDL Oxidation Susceptibility | Baseline, Week 4, Week 8 | Change from baseline in LDL oxidation susceptibility, measured as lag time using a copper-induced assay. |
| Secondary | Change in Malondialdehyde (MDA) Levels | Baseline, Week 4, Week 8 | Change from baseline in serum levels of malondialdehyde (MDA), an oxidative stress marker. |
| Secondary | Change in Oxidized LDL (oxLDL) Levels | Baseline, Week 4, Week 8 | Change from baseline in serum levels of oxidized low-density lipoprotein (oxLDL), an oxidative stress marker. |
| Secondary | Change in Total Antioxidant Capacity (TAC) | Baseline, Week 4, Week 8 | Change from baseline in serum total antioxidant capacity (TAC). |
| Other | Treatment-Emergent Adverse Events | Baseline, Week 4, Week 8 | Number and proportion of Treatment-Emergent Adverse Events (TEAEs). |
| Other | Treatment-Emergent Serious Adverse Events | Baseline, Week 4, Week 8 | Number and proportion of Treatment-Emergent Serious Adverse Events (TESAEs). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07881601/registered